Journal of Clinical and Aesthetic Dermatology

FEB 2018

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/934167

Contents of this Issue

Navigation

Page 54 of 62

52 JCAD JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY February 2018 • Volume 11 • Number 2 O R I G I N A L R E S E A R C H REFERENCES 1. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis. 2013;92(5):234–240. 2. Baldwin HE. Diagnosis and treatment of rosacea: state of the art. J Drugs Dermatol. 2012;11(6): 725–730. 3. National Rosacea Society site. Rosacea riddle now threatens more than 16 million Americans [press release]. 2010. Available at: http://www.rosacea.org/ press/archive/20100401.php. Accessed: March 9, 2016. 4. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584–587. 5. Del Rosso JQ, Gallo RL, Kircik L, Thiboutot D, Baldwin HE, Cohen D. Why is rosacea considered to be an inflammatory disorder? The primary role, clinical relevance, and therapeutic correlations of abnormal innate immune response in rosacea-prone skin. J Drugs Dermatol. 2012;11(6):694–700. 6. National Rosacea Society site. Drake L. Survey shows rosacea's emotional toll, positive effects of medical therapy. 2007. Available at: http://www.rosacea.org/ rr/2007/spring/article_3.php. Accessed: March 9, 2016. 7. van der Linden MM, van Rappard DC, Daams JG, et al. Health-related quality of life in patients with cutaneous rosacea: a systematic review. Acta Derm Venereol. 2015;95(4):395–400. 8. Beikert FC, Langenbruch AK, Radtke MA, Augustin M. Willingness to pay and quality of life in patients with rosacea. J Eur Acad Dermatol Venereol. 2013;27(6): 734–738. 9. Aksoy B, Altaykan-Hapa A, Egemen D, Karagoz F, Atakan N. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. Br J Dermatol. 2010;163(4): 719–725. 10. Moustafa F, Lewallen RS, Feldman SR. The psychological impact of rosacea and the influence of current management options. J Am Acad Dermatol. 2014;71(5):973–980. 11. Li J, Li M, Chen Q, et al. Quality of life among patients with rosacea: an investigation of patients in China using two structured questionnaires. J Eur Acad Dermatol Venereol. 2016;30(10):e98–e99. 12. Del Rosso JQ, Tanghetti EA, Baldwin HE, Rodriguez DA, Ferrusi IL. The burden of illness of erythematotelangiectatic rosacea and papulopustular rosacea: findings from a web-based survey. J Clin Aesthet Dermatol. 2017 June 1 [epub ahead of print]. 13. Lawrence JW, Heinberg LJ, Roca R, et al. Development and validation of the satisfaction with appearance scale: assessing body image among burn-injured patients. Psychol Assess. 1998;10(1):64–70. 14. Heinberg LJ, Kudel I, White B, et al. Assessing body image in patients with systemic sclerosis (scleroderma): validation of the adapted Satisfaction with Appearance Scale. Body Image. 2007;4(1): 79–86. 15. Ferrusi IL, Ahluwalia G, Andrae DA. Development and validation of the impact assessment for rosacea facial redness (IA-RFR) [poster]. Presented at: Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 20–24, 2017; Boston, MA. 16. Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107(5):707–713. 17. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433–1440. 18. Nicholson K, Abramova L, Chren MM, et al. A pilot quality-of-life instrument for acne rosacea. J Am Acad Dermatol. 2007;57(2):213–221. 19. McDowell I. The Short-form-36 Health Survey: Measuring Health: A Guide to Rating Scales and Questionnares. 3rd ed. New York, NY: Oxford University Press; 2006: 649–665. 20. Baldwin HE. A community-based study of the effectiveness of doxycycline 40 mg (30-mg immediate- release and 10-mg delayed-release beads) on quality of life and satisfaction with treatment in participants with rosacea. Cutis. 2010;86(5 Suppl):26–36. 21. Obidoa CA, Reisine SL, Cherniack M. How does the SF-36 perform in healthy populations? A structured review of longitudinal studies. J Soc Behav Health Sci. 2010;4(1):30–48. 22. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012;307(5): 491–497. 23. Coping with rosacea. 2016. Available at: http://www. rosacea.org/patients/materials/coping/managing. php#Managing. Accessed: March 29, 2016. 24. Huynh TT. Burden of disease: the psychosocial impact of rosacea on a patient's quality of life. Am Health Drug Benefits. 2013;6(6):348–354. 25. Fleischer A, Suephy C. The face and mind evaluation study: an examination of the efficacy of rosacea treatment using physician ratings and patients' self-reported quality of life. J Drugs Dermatol. 2005;4(5):585–590. 26. Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis. 2014;93(3): 134–138. 27. Bohm D, Schwanitz P, Stock GS, et al. Symptom severity and psychological sequelae in rosacea: results of a survey. Psychol Health Med. 2014;19(5):586–591. JCAD

Articles in this issue

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - FEB 2018